ALSUntangled #77: Psilocybin

Area of Science:

• Neuroscience
• Pharmacology
• Amyotrophic Lateral Sclerosis (ALS) Research

Background:

• Patient interest in alternate and off-label treatments for ALS is growing.
• Psilocybin, a psychedelic compound from mushrooms, is being explored for therapeutic potential.

Purpose of the Study:

• To review the potential of psilocybin as a disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS).
• To assess the current evidence and risks associated with psilocybin use in the context of ALS.

Main Methods:

• Literature review of psilocybin's properties and potential effects on neurogenesis and inflammation.
• Assessment of existing pre-clinical models, case reports, and clinical trials related to psilocybin and ALS.

Main Results:

• Psilocybin can cross the blood-brain barrier and has plausible mechanisms for impacting neurogenesis and inflammation.
• There are currently no pre-clinical ALS models, case reports, or trials evaluating psilocybin for ALS disease modification.
• High risk of psychological side effects (hallucinations) and physical harm exists, dependent on dosage.

Conclusions:

• The use of psilocybin is not currently supported as a means to slow ALS progression due to insufficient evidence and potential risks.
• Further research is needed to establish the safety and efficacy of psilocybin for ALS treatment.